- Conditions
- End Stage Renal Disease
- Interventions
- Drotrecogin alfa activated (Xigris)
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 753
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Failure, Chronic
- Interventions
- Obinutuzumab, Intravenous Immunoglobulin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 4 more
- Conditions
- End Stage Kidney Disease, Depressive Symptoms
- Interventions
- Joviality(TM), Inert Virtual Reality
- Behavioral · Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois
- Conditions
- Calciphylaxis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Kidney Failure, Chronic
- Interventions
- Prehabilitation
- Other
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Lutherville, Maryland
- Conditions
- Dementia, Cognition, End-stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Failure
- Interventions
- Kibow Biotics/Renadyl
- Dietary Supplement
- Lead sponsor
- Kibow Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Arterio-venous Fistula, Kidney Failure, Hemodialysis Access Failure
- Interventions
- Exercise
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
- Interventions
- paricalcitol
- Drug
- Lead sponsor
- Renal Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
- Interventions
- Allogeneic islets of Langerhans
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- End Stage Kidney Disease
- Interventions
- Standard Table Salt, Salt Substitute
- Dietary Supplement
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
- Interventions
- iChoose Kidney Decision Aid
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York
- Conditions
- End Stage Renal Disease, Thrombosis
- Interventions
- AB002 Dose 1, AB002 Dose 2, placebo
- Drug
- Lead sponsor
- Aronora, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Hypertensive Renal Disease
- Interventions
- USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
- Behavioral · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
- Conditions
- End-Stage Renal Disease
- Interventions
- Nudge for PHPC Referral
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- End-Stage Renal Disease, Diabetes Mellitus
- Interventions
- IV Novolin R human insulin
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Renal Impairment
- Interventions
- Tasimelteon
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Restless Legs Syndrome
- Interventions
- ropinirole dosing for up to 28 days
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- End Stage Renal Disease
- Interventions
- nutritional supplementation, exercise
- Drug · Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- End-Stage Renal Disease
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Quality of Life, Depression, End Stage Renal Disease, Disability Physical
- Interventions
- CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- End Stage Renal Disease, Chronic Kidney Diseases
- Interventions
- Berinert, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- End Stage Renal Disease
- Interventions
- MEDI-507, Rituximab, Total Body Irradiation, Thymic Irradiation
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Renal Disease, Living Donor Kidney Transplantation, Renal Dialysis
- Interventions
- COACH (Communicating about Choices in Transplantation)
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania